Startup profile · funding coverage
Altay Therapeutics funding, valuation and investors
Develops oral small-molecule transcription-factor inhibitors, led by DX5057 for FSHD.
Keep track of Altay Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
US$37 million · October 14, 2026
Latest known valuation
Undisclosed
Series A · October 14, 2026
Total disclosed equity funding
$37M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · San Carlos, California, United States
Investors in latest funding
Lead: Sound Bioventures , HealthCap
Other: Fountain Healthcare Partners , Biogen New Ventures , Pappas Capital , Global BioAccess Fund
Overview
Altay Therapeutics is a San Carlos, California biotechnology company developing investigational small-molecule transcription-factor inhibitors. It closed a $37 million Series A announced October 14, 2026, co-led by Sound Bioventures and HealthCap, with Fountain Healthcare Partners, Biogen New Ventures, Pappas Capital and Global BioAccess Fund participating. The valuation was undisclosed.
Why Altay Therapeutics is interesting
A $37 million Series A finances the transition from preclinical DUX4 biology into human testing, offering a different delivery approach from RNA therapeutics.
Product & use cases
DX5057 is an investigational oral DUX4 inhibitor for facioscapulohumeral muscular dystrophy. Altay expects Phase 1 safety testing to begin in Q1 2027 and plans Phase 2 proof-of-concept work. That timetable is a company target, not evidence of human efficacy or approval.
Funding history (newest first)
Series A
2026-10-14T00:00:00Z US$37 million Valuation: Undisclosed- Sound Bioventures (lead)
- HealthCap (lead)
- Fountain Healthcare Partners (participant)
- Biogen New Ventures (participant)
- Pappas Capital (participant)
- Global BioAccess Fund (participant)
Investors in our directory
Funds linked from Altay Therapeutics's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Oral delivery could simplify chronic treatment if sufficient safe exposure and clinical benefit can be demonstrated. Its platform targets allosteric pockets on transcription factors.
Lead-program value remains dependent on human safety, target engagement and functional outcomes. Oral convenience and preclinical signals cannot establish superiority to other therapeutic modalities.
-
Soufflé Therapeutics adjacent
Recently financed RNA-delivery company with an FSHD program; different modality and development strategy.
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover Altay Therapeutics's financing or category context.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.